Novanta Inc. (NOVT) | The Buildout — AI Infrastructure
The Verdict
Novanta supplies precision laser beam steering, air bearing spindles, servo drives, precision motion, and photonics to equipment makers that produce AI chips, package substrates, and robots. The same portfolio also supports medical and advanced industrial OEMs. Its AI infrastructure role is indirect but embedded: its subsystems go into probe-card tools, thick GPU-board drilling, lithography light engines, and robotics rather than into data centers or AI models directly.
| Market Cap | — |
| Revenue (TTM) | $1.0B |
| Revenue Growth | +5.6% |
| EBITDA Margin (TTM) | 17.9% |
| Net Cash | $98M |
| Earnings Beats | 5 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- AI-related applications were about 17% of legacy revenue in Q2 2026, up from about 15% in Q1, and grew about 25% y/y by management estimate.
- AET adjusted gross margin reached about 53% in Q2, up 450bps y/y and 470bps sequentially, despite tariff and redundancy costs.
- H1 operating cash flow was $117M; Q2 operating cash flow was $65M versus $15M in the prior-year quarter.
- Riverpoint roughly doubles recurring medical consumables to about $300M and moves medical end-market exposure to about 60% of revenue.
- Air bearing spindle demand is committed for the next two years, and the China capacity expansion is partially customer-funded.
What We’re Watching
- Medical Solutions quarterly book-to-bill was 0.79 in Q2; next quarters show whether the 4-quarter average above 1.0 holds.
- Medical Solutions adjusted gross margin was about 41% in Q2, down 290bps y/y; the guided total-company Q3 margin of about 48% is the recovery test.
- Precision Medicine is expected to decline in Q3 2026, and life sciences growth is targeted for late 2027.
- Riverpoint integration risk includes Q3 gross debt just north of $800M and pro forma gross leverage around 2.7x.
The thesis is strengthening on the AET side: organic growth stepped from 3% in Q1 to 9% in Q2, bookings and backlog remain positive, and cash conversion is unusually strong. The medical side is more mixed—Riverpoint improves the long-term mix, but Medical Solutions book-to-bill and margins trailed. The key open question is whether Medical Solutions returns above 1.0 book-to-bill and expands margin as guided, proving the acceleration is not only an AET story.
Earnings Beat
Novanta reported Q2 2026 revenue of $265.8 million, up about 10% from $241.0 million a year earlier. Adjusted gross margin was 47%, up 100bps y/y and 150bps sequentially, while adjusted EBITDA was about $60.7M, up 16% y/y.
| Metric | Q1 FY2026 | Q4 FY2025 | Q1 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $258M | $258M | $233M | +10.4% |
| Gross margin | 41.8% | 40.7% | 42.3% | -50bps |
| EBITDA | $44M | $48M | $44M | +1.8% |
| EPS | $0.51 | $0.45 | $0.59 | −12.8% |
| AET book-to-bill | 1.1 | 1.15 | n/a | — |
| Medical Solutions book-to-bill | 0.79 | 1.04 | n/a | — |
Year-to-date operating cash flow was $117 million, which is already exceeding the operating cash flows we delivered for the full year of 2025.— Robert Buckley, Chief Financial Officer, August 6, 2026
Management tone: Management's tone shifted from confident-and-disciplined in Q1 to more forceful in Q2 after two facility closures completed, a gross-margin step-up, the Riverpoint close, and full-year guidance raised across revenue, EBITDA, and EPS. On life sciences, tariffs, and Medical Solutions book-to-bill, management stayed direct and cited rolling averages or late-2027 recovery timing.
Management Guidance
For Q3 2026, management guided revenue to $300M–$304M, adjusted gross margin of about 48%, adjusted EBITDA of $74M–$77M, and adjusted EPS of $0.95–$1.00. Full-year 2026 guidance was raised to revenue of $1,130M–$1,140M, adjusted EBITDA of $273M–$278M, and adjusted EPS of $3.68–$3.74, with adjusted gross margin around 47%. Management said the guide includes conservatism because Riverpoint had never closed a quarter as a public company.
Trajectory
Revenue is accelerating: trailing quarterly revenue moved from $241M in Q2 2025 to $248M, $258M, and $258M, and Q2 2026 reported revenue reached $265.8M. Organic growth jumped from 3% in Q1 to 9% in Q2. Overall margin trends are stable, but the mix is unbalanced—AET adjusted gross margin rose to about 53% in Q2, while Medical Solutions adjusted gross margin fell to about 41%.
The Model
The model projects FY+1 revenue of $1,070M and EBITDA of $215M, a 20.1% margin, and FY+2 revenue of $1,200M and EBITDA of $253M, a 21.1% margin. The near-term anchor is AET order conversion plus Riverpoint's first full-year contribution; FY+2 depends on AI, robotics, and semiconductor demand holding, and on margin gains from consolidation and medical mix.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $980M | $1.1B | $1.2B |
| YoY Growth | — | +9.1% | +12.1% |
| EBITDA | $179M | $215M | $253M |
| EBITDA Margin | 18.2% | 20.1% | 21.1% |
Projections are the median of 5 independent model runs. The model’s revenue sits 6.7% above analyst consensus.
For Q3 2026, management guided revenue to $300M–$304M, adjusted gross margin of about 48%, adjusted EBITDA of $74M–$77M, and adjusted EPS of $0.95–$1.00. Full-year 2026 guidance was raised to revenue of $1,130M–$1,140M, adjusted EBITDA of $273M–$278M, and adjusted EPS of $3.68–$3.74, with adjusted gross margin around 47%. Management said the guide includes conservatism because Riverpoint had never closed a quarter as a public company.
What Could Go Right — and Wrong
- AI-related demand accelerates further and broadens beyond the 17% legacy mix as humanoid and NVIDIA Halos revenue moves to commercial scale.
- Medical Solutions margins recover sequentially, with total adjusted gross margin holding toward the guided 48% in Q3 and around 47% for FY2026.
- Riverpoint delivers the guided H2 contribution—$60–65M revenue and about $25M adjusted EBITDA—and doubles consumables without disruption.
- Air-bearing spindle capacity expansion in China completes cleanly and converts two years of committed demand into revenue.
- Two additional factory closures by Q1 2027 produce the expected margin and complexity benefits.
- AI/semiconductor equipment spending pauses or humanoid adoption slips, reversing AET revenue and margin acceleration.
- Medical Solutions quarterly book-to-bill stays below 1.0, showing the 0.79 was not just annual PO timing.
- Tariffs remain net negative and surcharging fails to absorb further increases, compressing margins.
- Riverpoint integration, private-to-public reporting, and pro forma gross leverage around 2.7x cause disruption or slower contribution.
- Life sciences stays weak beyond late 2027, keeping Precision Medicine a drag.
Looking Ahead
The next 12 months test whether Q2's acceleration is durable. Q3 2026 is the first consolidated quarter for Riverpoint and a margin checkpoint; into early 2027, two additional factory closures and the China spindle capacity doubling are expected to proceed. EUV/DUV business is expected to ramp in H2 2026, while NVIDIA Halos and humanoid revenue are expected to be more meaningful in 2027.
- Q3 2026First consolidated Riverpoint quarter — Tests Riverpoint contribution, total margin near 48%, and Medical book-to-bill.
- H2 2026EUV/DUV ramp — Delayed new business expected to contribute meaningfully in H2 and more in 2027.
- End Q1 2027Two additional plant closures — Management expects production moves and transfers complete by then.
- 2027NVIDIA Halos revenue — Management expects Halos revenue to become more meaningful in 2027.
- Late 2027Precision Medicine recovery — Management targets life sciences growth returning in late 2027.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $949M | $980M | $1.0B | +3.3% |
| Gross Margin | 44.4% | 41.6% | 41.5% | 282bps |
| EBITDA | $166M | $179M | $1.3B | +7.5% |
| EBITDA Margin | 17.5% | 18.2% | 17.9% | +72bps |
| Net Income | $64M | $54M | $54M | -16.0% |
| Free Cash Flow | $141M | $48M | $825M | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)41.5%
- EBITDA Margin (TTM)17.9%
- Net Margin (TTM)5.4%
- ROIC7.6%
- FCF Conversion37.5%
- SBC / Revenue2.2%
The Company
Novanta supplies core technology solutions to medical, life science, and advanced industrial OEMs across two reportable segments: Automation Enabling Technologies (AET) and Medical Solutions. AET sells laser beam steering and scanning, laser sources, robotic and precision motion, robotic end-of-arm tooling, and air bearing spindles. Medical Solutions sells medical insufflators, endoscopic pumps and disposables, imaging/identification/RFID, advanced motion control, light engines, and integrated operating room technologies.
The company operates as an upstream, design-in component and subsystem supplier embedded in customer equipment. It has more than 20 manufacturing sites across the United States, United Kingdom, Europe, and China, and is consolidating them into regional centers of manufacturing excellence; two closures were completed in Q2 2026 and two more are targeted by end Q1 2027.
Business Segments
Competitive Landscape
The direct competitor set is not named in the supplied filings or calls. Management's defensibility claims center on precision and certification: it describes itself as '#1 by far' in thick GPU board drilling and says it is, as far as it is aware, the only servo-drive manufacturer selected for NVIDIA's Halos lab. Air bearing spindle demand is committed for two years and the capacity expansion is partly customer-funded, which management frames as difficult to replace near term.
Supply Chain
Novanta sits upstream of OEMs as a component and subsystem supplier, feeding semiconductor equipment, robotics, and medical devices. No supply-chain neighbor mentioned Novanta directly; neighbor read-throughs are inferential.
More on NOVT: Earnings recap